A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid TumorsGeoffrey Y. Ku, Samuel J. Klempner, Lin Shen et al.|Clinical Cancer Research|2025Cited by 16
Study on the anti‐atherosclerotic mechanisms of immune tolerance induced by heat shock protein 60Chunyan Hao, Wang Fengzhi, Xuejun Liu et al.|The FASEB Journal|2013Cited by 0